Quarterly ResultMay 6, 2026, 04:21 PM
Penumbra Q1 Revenue $374.8M, up 15.6%; Net Income $32.6M
AI Summary
Penumbra Inc. reported its financial results for the first quarter ended March 31, 2026, with revenue increasing by 15.6% to $374.8 million compared to the prior year. Net income for the quarter was $32.6 million, a decrease from $39.2 million in Q1 2025, partly due to higher operating expenses which included $9.4 million in acquisition-related costs. The company also announced that it would not be providing full-year 2026 financial guidance or hosting a conference call due to its pending acquisition by Boston Scientific Corporation.
Key Highlights
- Revenue for Q1 2026 was $374.8 million, an increase of 15.6% compared to Q1 2025.
- Net income for Q1 2026 was $32.6 million, down from $39.2 million in Q1 2025.
- Gross profit margin was 67.6% in Q1 2026, a 1.0% increase from Q1 2025.
- Global thrombectomy revenue grew 12.1% to $253.9 million in Q1 2026.
- Global embolization and access revenue increased 23.8% to $120.8 million in Q1 2026.
- Total operating expenses were $215.2 million, including $9.4 million in acquisition-related costs.
- The company will not provide full-year 2026 financial guidance due to a pending acquisition.